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Section A. Physical, chemical, pharmaceutical and 
pharmacological information 
A1. Physical, chemical, and pharmaceutical information 
A1.1. Physical and chemical description 
Chemical description and names 
5-(2-Aminopropyl)indole is a synthetic derivative of indole substituted at the phenyl side of 
the indole ring system (position 5). It is a positional isomer of alpha-methyltryptamine (AMT) 
which belongs to the tryptamine family, many of which show hallucinogenic and other 
psychoactive effects in humans. 5-(2-Aminopropyl)indole also contains the sub-structure of 
alpha-methylphenethylamine and therefore could be considered to be a substituted 
phenethylamine, many of which are stimulants. Limited data suggests that 5-(2-
aminopropyl)indole has stimulant effects and possible hallucinogenic effects.   
The systematic (International Union of Pure and Applied Chemistry, IUPAC) name of 5-(2-
aminopropyl)indole is 1-(1H-indol-5-yl)propan-2-amine and other names that may be 
encountered include α-methyl-1H-indole-5-ethanamine and 2-(1H-indol-5-yl)-1-methyl-
ethylamine. A common abbreviation used for 5-(2-aminopropyl)indole is 5-IT (1). To a lesser 
extent the abbreviation 5-API is also used (2). Both these abbreviations are used by Internet 
retailers (3) advertising 5-(2-aminopropyl)indole as well as in Internet drug user discussion 
forums (‘drug discussion forums’). This suggests that '5-IT' and '5-API' are used as 'street 
names'. The Chemical Abstract Service (CAS) Registry Numbers for 5-(2-
aminopropyl)indole are given in Table 1. 
Table 1. Chemical Abstract Service (CAS) Registry Numbers for 5-(2-aminopropyl)indole 
 
CAS Registry Numbers Variant 
3784-30-3 Unspecified amine 
 
96875-04-6 Ethanedioate (1:1) / hydrogen oxalate / bioxalate 
 
1336260-35-5 (R)-Enantiomer amine 
 
1336564-72-7 (S)-Enantiomer amine 
 
 
 
Excluding the abstractable proton on the nitrogen atom a total number of six positional 
isomers exist that can carry the 2-aminopropyl side chain. The synthesis of 5-(2-
aminopropyl)indole (Figure 1) and its isomers was first described by Hofmann and Troxler 
(1963) and Troxler et al., (1968). Another isomer is N-methyltryptamine (NMT) which is 
                                                     
(1)  The origin of the abbreviation ‘5-IT’ is not known at this time.  
(2)  The origin of the abbreviation ‘5-API’ is thought to be derived from 5-(2-aminopropyl)indole. 
(3) The term 'Internet retailers' is used in this report to describe Internet shops that offer new psychoactive substances 
for sale often advertised as 'legal highs' and 'research chemicals'.  
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commonly found in nature (Ott, 1996). A more recent example of the preparation of 2-(2-
aminopropyl)indole (2-IT) was presented by Alhambra et al., (2001) who employed a solid-
phase approach. The synthesis of the 3-(2-aminopropyl)indole (AMT) (4) isomer was first 
published in 1947 (Snyder and Katz, 1947). 5-(2-Aminopropyl)indole contains an asymmetric 
carbon but data on the availability of its enantiomeric forms on the market (including seized, 
collected and biological samples referred to in this report) are currently not available.  
Figure 1. The numbered molecular structure, formula, weight and monoisotopic mass of 5-(2-
aminopropyl)indole (5). Asterisk indicates chiral centre. 
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Molecular formula: C11H12N2 
 
Molecular weights: 174.24 g/mol (base) 
 
Monoisotopic mass: 174.1157 Da 
 
 
 
Identification and analytical profile 
The free base gives a slightly violet response (Keller test) whereas the van Urk test results in 
the formation of a red colour (Hofmann and Troxler, 1963). Further information on the 
presumptive tests for 5-(2-aminopropyl)indole are not available. The reported melting points 
are: 81–83 °C (free base) (petroleum ether/benzene) (Hofmann and Troxler, 1963 and 
Troxler et al., 1968); 199–201 °C (bioxalate salt) (methanol/diethyl ether) (Hofmann and 
Troxler, 1963); 194 °C (dec.) (hemisuccinate) (LGC GmbH, 2012). Analysis by high 
performance liquid chromatography diode array detection gave λmax values at 218.3 nm 
and 272.8 nm (Elliott et al., 2013).  
Nuclear magnetic resonance spectroscopy (NMR) data of 5-(2-aminopropyl)indole succinate 
(6): 1H NMR (300 MHz, CD3OD): δ 7.42 (1H, br d, J = 1.1 Hz, H-4), 7.37 (1H, d, J = 8.3 Hz, 
H-7), 7.23 (1H, d, J = 3.2 Hz, H-3), 6.98 (1H, dd, J = 8.3 Hz, J =1.7 Hz, H-6), 6.41 (1H, dd, J 
= 3.2 Hz, J = 0.8 Hz, H-2), 3.57-3.45 (1H, m (consistent with predicted dqd), α-CH), 3.02 
(1H, dd, Jgem = 13.8 Hz, 3J = 6.5 Hz, CHAHB), 2.86 (1H, dd, Jgem = 13.8 Hz, 3J = 8.0 Hz, 
CHAHB), 2.51 (4H, s, succinate), 1.26 (3H, d, 3J = 6.6 Hz, CH3). 13C NMR (75 MHz, CD3OD): 
δ 179.4 (succinate), 137.0 (C-7a), 129.9 (C-3a), 127.5 (C-5), 126.3 (C-3), 123.5 (C-6), 121.8 
(C-4), 112.6 (C-7), 102.2 (C-2), 50.8 (α-CH), 42.2 (CH2), 32.9 (CH2, succinate), 18.5 (CH3) 
(Elliott et al., 2013). 
                                                     
(4)  Abbreviations and code names for AMT found in the literature include: α-methyltryptamine, AMT, α-MT, 3-IT, IT-290, 
IT-403, U-14, 162-E, Ro 3-0926, NSC 97069, and Indopan. 
(5) For additional predicted data, see http://www.chemspider.com/Chemical-Structure.25991467.html 
(6) NMR data is provided for 5-(2-aminopropyl)indole succinate as this is the form that was encountered in a collected 
sample that was analysed. 
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Mass spectrometry data: 5-(2-aminopropyl)indole (5-IT) and 3-(2-aminopropyl)indole (AMT) 
have been found to produce virtually identical mass spectra, especially when applying 
conventional electron ionization mass spectrometry (EI-MS) procedures. Thus, all six 
potential 2-aminopropyl isomers may be expected to yield very similar mass spectra. 
However, the implementation of suitable chromatographic techniques would be expected to 
allow successful separation if the reference materials are available for comparison.  
Consistent with mass spectral behaviour reported for isomeric psychoactive tryptamines 
(Martins et al., 2010), key fragments observed under EI-MS conditions (m/z) were: 44 (base 
peak), 131, 130, 77, 103, 117. The M●+ (m/z 174) may be detectable at a minor relative 
abundance but may also be absent. CI-MS (MeOH as liquid CI reagent) gave the [M+H]+ at 
m/z 175 as the base peak and a prominent fragment at m/z 158 following the loss of NH3. 
Positive electrospray tandem mass spectra (ESI-MS/MS) yielded m/z values of 77, 103, 117, 
130, 143, 158 (relative abundance values dependent on collision energy) with some in-
source fragmentation of the protonated molecule at m/z 175. When evaluating the ability to 
differentiate between 5-IT and AMT under ESI-MS/MS conditions, distinct differences in the 
relative abundances were observed, allowing for the potential use of ion ratios for multiple 
reaction monitoring (MRM) transitions. Thus, for AMT: m/z 175/158 (100 % abundance), m/z 
175/143 (78 %), m/z 175/130 (30 %) and for 5-IT: m/z 175/158 (100 % abundance), m/z 
175/143 (22 %), m/z 175/130 (84 %) (Elliott et al., 2013).  
The REACH (Regulation on Registration, Evaluation, Authorisation and Restriction of 
Chemicals) registered substances database hosted by the European Chemicals Agency 
(ECHA) was searched using the CAS Registry Numbers listed above and no information 
was found. 
The lack of a rapid qualitative screening method is a limiting factor for the detection of 5-(2-
aminopropyl)indole in biological samples. Furthermore, many European 
forensic/toxicological laboratories may not have procedures in place for analysing 5-(2-
aminopropyl)indole in biological samples. In some cases this may be due to the lack of 
reference standards for the drug or difficulties in distinguishing between 5-(2-
aminopropyl)indole and the related compound AMT. 
Physical description  
The free base form of 5-(2-aminopropyl)indole has been described to form skewed prisms 
(Troxler et al., 1968) and the bioxalate salt form has also been documented (Hofmann and 
Troxler, 1963). It has been reported that some Internet retailers have advertised 5-(2-
aminopropyl)indole as the succinate salt. NMR data produced as part of the analysis of two 
collected samples of 5-(2-aminopropyl)indole (reported by the United Kingdom) were found 
to be consistent with the succinate form (see data above). The structured Internet search 
conducted by the EMCDDA for the Joint report also noted that 5-(2-aminopropyl)indole 
hydrochloride was being offered for sale (EMCDDA & Europol, 2012). Analytical reference 
standards are commercially available (7). See section A1.2 for a description of the physical 
                                                     
(7)  For example http://www.logical-
standards.com/index.php?mact=Products,cntnt01,details,0&cntnt01productid=1811&cntnt01returnid=57; and, 
 5 
forms that have been reported. 
Methods and chemical precursors used for the manufacture of 5-(2-aminopropyl)indole 
There is currently no information regarding manufacturing sites, the chemical precursors or 
the synthetic routes used for the 5-(2-aminopropyl)indole that has been detected on the drug 
market.  
One classic approach used for the synthesis of 5-(2-aminopropyl)indole includes a 
condensation reaction using indole-5-carboxaldehyde and nitroethane. These substances 
are commercially available and are not under international control. The resulting 5-(2-methyl-
2-nitrovinyl)indole can then be reduced with lithium aluminium hydride (LiAlH4) (Hofmann 
and Troxler, 1963; Troxler et al., 1968). Other methods and reagents of reduction, for 
example those also employed during phenylalkylamine synthesis, may equally be useful 
(Guy et al., 2008). The reactions are feasible in an amateur laboratory setting and do not 
require sophisticated equipment. In analogy to the reductive amination procedure used to 
obtain a range of phenylalkylamines, the use of 1-(1H-indol-5-yl)propan-2-one as a potential 
starting material might also be conceivable. However, an example of this manufacturing 
procedure is not available in the literature.   
Typical impurities encountered in seized samples 
There is currently no information available with regards to route-specific by-products 
produced during the synthesis of 5-(2-aminopropyl)indole. In addition there is no data 
currently available on the impurities detected in seized and collected samples.   
In some samples, 5-(2-aminopropyl)indole has been reported to be the only psychoactive 
substance detected. Additionally, although not impurities, there have been a small number of 
reports where 5-(2-aminopropyl)indole has been found in combination with other 
psychoactive substances. These include: 5,6-methylenedioxy-2-aminoindane (MDAI) in 
Germany; methylthienylpropamine (1-(thiophen-2-yl)-2-methylaminopropane, MPA) and 
caffeine in tablets bearing markings resembling the Lexus logo (8) in Hungary; 
diphenyl(pyrrolidin-2-yl)methanol (diphenylprolinol, D2PM) in capsules in Guernsey (9); and, 
ethylphenidate within a beige powder in Sweden. No quantitative data were provided for any 
seized or collected sample reported to the EMCDDA nor Europol. 
A1.2. Physical/pharmaceutical form  
Reports of seizures and collected samples have noted that 5-(2-aminopropyl)indole has 
been detected in: brown, pale/light brown or beige powders; beige tablets bearing markings 
resembling the Lexus logo; brown glittery tablets; blue/green unmarked tablets; blue 
unmarked tablets commercially packaged as 'BENZO FURY'; capsules; and, in residues on 
                                                                                                                                                                     
https://www.caymanchem.com/app/template/Product.vm/catalog/12042;jsessionid=4E0344937486009FBED6743CF
B66E902 
(8) It is common to find markings on tablets sold as 'ecstasy' including those of popular cultural and iconic brands often 
having an association with quality. Lexus is a luxury Japanese car manufacturer. 
(9)  British Crown Dependency of the Bailiwick of Guernsey, report received from the United Kingdom national focal 
point. 
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a spoon and in the liquid recovered from a syringe. See section C for further details of the 
seized and collected samples of 5-(2-aminopropyl)indole. 
A1.3. Route of administration and dosage  
As noted, 5-(2-aminopropyl)indole has been encountered as powders as well as tablets and 
capsules. These physical forms suggest that common routes of administration may be oral 
and by insufflation. Limited information from reports of non-fatal intoxications, deaths and 
drug discussion forums appear to support this (see below). The succinate salt of 5-(2-
aminopropyl)indole, confirmed in the two collected samples reported by the United Kingdom, 
may be suitable for injection. Significantly, in this respect, Hungary has reported that 5-(2-
aminopropyl)indole has been found in residues on a spoon and in the liquid recovered from 
a syringe. The assessment of the national focal point is that 5-(2-aminopropyl)indole is being 
injected in some cases.  
In two non-fatal intoxications the route of administration was reported as by nasal 
insufflation.  A user report from Shulgin and Shulgin (1997) noted an example of oral 
administration of 20 mg. Drug discussion forums suggest that routes of administration 
include: oral ingestion (swallowing, such as ‘bombing’ (10)), nasal insufflation (snorting), 
sublingual, intravenous injection, and rectal insertion (11). Reported doses used include: 
‘20mg’ [route of administration not specified], ‘80 mg orally’, ‘bombed 100 mg’, ‘150Mg 
swallowed’, ‘insufflated 65 mg’(12). 
A2. Pharmacology, including pharmacodynamics and pharmacokinetics  
Pharmacodynamics 
While detailed pharmacological investigations on 5-(2-aminopropyl)indole do not appear to 
have been published (13), one study was identified that investigated the ability of 5-(2-
aminopropyl)indole and its five isomers to inhibit monoamine oxidase (MAO). The assay 
method was based on the ability of guinea pig liver homogenate to absorb oxygen generated 
from serotonin as the substrate. The activity was expressed as percentage inhibition. The 
IC50 values for 5-(2-aminopropyl)indole, 6-(2-aminopropyl)indole (6-IT) and 3-(2-
aminopropyl)indole (AMT), for example, were 22, 4.6 and 58 µM, respectively. These data 
indicate that 6-IT was the most potent inhibitor amongst those three substances. These 
substances were also evaluated for their ability to antagonise pentylenetetrazole/reserpine-
induced tonic extensor seizures in mice. 5-(2-Aminopropyl)indole appeared to be less active 
than 6-IT but more active than AMT with regards to anti-reserpine activity (Cerletti et al., 
1968). While the AMT isomer has been shown to induce stimulant effects in mice (including 
body tremor, heightened locomotor activity, mydriasis and hyperthermia) (Lessin et al., 
                                                     
(10) ‘Bombing’ is where a drug is wrapped in cigarette paper (or similar) prior to swallowing. 
(11) http://www.drugs-forum.com/forum/showpost.php?p=1126167&postcount=9 
(12) http://www.drugs-forum.com/forum/showthread.php?t=140331 
http://www.drugs-forum.com/forum/showthread.php?t=172223 
http://www.bluelight.ru/vb/threads/616728-The-Big-amp-Dandy-5-IT-5-API-Thread 
(13) A literature search on 5-(2-aminopropyl)indole revealed a translated article (USSR, Academy of Sciences) on 
serotonergic properties of several tryptamines. However, inspection of the English translation did not appear to 
provide any data on 5-(2-aminopropyl)indole (Buznikov et al., 1965). 
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1965), the extent to which this extends to the remaining isomers, including 5-(2-
aminopropyl)indole, remains to be studied. A short report on the 6-(2-aminopropyl)indole 
isomer provided some indication that intravenous administration (0.5 mg/kg) resulted in 
hypertension and related sympathomimetic features in dogs (Maxwell, 1964). 
Given the lack of information on the pharmacological and toxicological properties of 5-(2-
aminopropyl)indole, and drawing on the study by Cerletti et al., (1968) summarised above, 
the EMCDDA commissioned a study designed to provide further data on the possible effects 
of 5-(2-aminopropyl)indole on monoamine oxidase inhibition (Appendix 1). This study used 
an in vitro assay with recombinant human MAO-A and B isoenzymes (using kynuramine as 
substrate) based on the procedure published by Herraiz and Caparro (2006). The study 
found that racemic 5-(2-aminopropyl)indole (in the form of the hemisuccinate salt) is a 
reversible, competitive and highly selective inhibitor of MAO-A (IC50 of 1.6 µM and Ki of 0.25 
µM) but not MAO-B. In addition, an in vitro experimental comparison found 5-(2-
aminopropyl)indole to be less potent than the known MAO-A inhibitors clorgyline and 
harmaline, but more potent than toloxatone and moclobemide (Table 2).  
Table 2. Inhibition values determined from recombinant human monoamine oxidase-A assay. 
Racemic 5-(2-aminopropyl)indole was used in the form of the hemisuccinate salt. 
Compound IC50 (µM) Ki (µM) Ki (µM) from IC50 
Clorgyline 0.016 - 0.016 
 
Harmaline 0.020 - 0.004 
 
5-(2-Aminopropyl)indole 1.6 0.25 0.32 
 
Toloxatone 6.7 - 1.3 
 
Moclobemide >500 - - 
 
 
Shulgin and Shulgin (1997) reported long-lasting stimulant properties of around 12 hours 
duration following oral administration of 20 mg. Currently, no data are available on the 
presence and/or properties of single enantiomers. Increased potency was found to reside 
with the (S)-(+)-enantiomer of AMT in both animals and humans (Nichols, 1986). Whether a 
similar relationship exists with 5-(2-aminopropyl)indole remains to be investigated.  
There are appears to be no published data on the biotransformation (metabolism) of 5-(2-
aminopropyl)indole in animals or humans. Since this particular isomer carries the side chain 
at the 5-position it is currently unknown whether similar transformations occur that have 
been observed with AMT. Early work carried out in vitro (in rat liver microsomes) and in vivo 
samples (male albino rat urine following intraperitoneal injection of 5 mg/kg AMT and 
incubation with bacterial β-glucuronidase) indicated the presence of 6-hydroxy-AMT, 1-(1H-
indol-3-yl)propan-2-one and 1-(6-hydroxy-1H-indol-3-yl)propan-2-one, respectively (Szara, 
1961). A more recent example of metabolic studies in rats was provided by Kanamori et al. 
(2008) who observed the formation of 3-(2-aminopropyl)indolin-2-one, 2-amino-1-(1H-indol-
3-yl)propan-1-ol, 6-hydroxy-AMT and 7-hydroxy-AMT in urine following enzymatic 
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hydrolysis. In this study, four male Wistar rats received an oral dose of 10 mg/kg of AMT 
with urine collected and pooled over a 24 hour period. Overall, AMT was found to be poorly 
metabolised, as indicated by the relative contribution of signal intensities under GC-MS 
conditions. 
Interactions with other drugs and medicines 
Given the limited information that is available on the pharmacology of 5-(2-
aminopropyl)indole it is difficult to predict with accuracy any particular potential drug 
interactions or contraindications. However, as stated above, the ability of 5-(2-
aminopropyl)indole to inhibit MAO-A in vitro may result in potential interactions with drugs 
acting on the monoaminergic system. In particular this may be the case for serotonergic 
drugs that may present a risk of inducing serotonin syndrome, the symptoms of which can 
include tachycardia, hyperthermia, muscle rigidity and convulsions (Boyer & Shannon, 
2005). In the context of 5-(2-aminopropyl)indole use, there may be a potential risk from the 
(concomitant) use of medicinal products (e.g. selective serotonin reuptake inhibitors 
(SSRIs)) as well as stimulant drugs that act on the monoaminergic system. These include 
amphetamine, MDMA (and other phenethylamines) and cathinone derivatives (e.g. 
mephedrone, 4-methylethcathinone). In this respect, some of these drugs have been 
detected in the biological samples from the non-fatal intoxications and deaths detailed in 
section D. It may be the case that a possible synergistic interaction may have played a role 
in these cases.  
Pharmacokinetics 
No animal studies were identified that investigated the pharmacokinetics of 5-(2-
aminopropyl)indole. There is limited information available from Internet reports or from drug 
discussion forums that could be used to determine pharmacokinetic parameters such as 
time of onset of desired effects, adverse effects, or duration of action of 5-(2-
aminopropyl)indole. As noted, Shulgin and Shulgin (1997) provided some limited information 
noting that 5-(2-aminopropyl)indole has long-lasting stimulant effects in humans of about 
twelve hours when 20 mg is given orally. 
A3. Psychological and behavioural effects 
No studies were identified that investigated the psychological and/or behavioural effects of 
5-(2-aminopropyl)indole. As mentioned above, Shulgin and Shulgin (1997) provided some 
limited information noting that 5-(2-aminopropyl)indole may show long-lasting stimulant 
properties in humans for about twelve hours when 20 mg is given orally. The physical effects 
reported were increased heart-rate, anorexia, diuresis, and slight hyperthermia. No further 
relevant details were reported. Section D1.2.1. discusses some of the effects that have been 
self-reported by users on drug discussion forums. 
A4. Legitimate uses of the product  
5-(2-Aminopropyl)indole is available as an analytical reference standard and is used in 
scientific research. 5-(2-Aminopropyl)indole is mentioned in patents that claim derivatives of 
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this compound and a broad range of other arylethylamines as pro-drugs which may have 
potential medicinal applications (Jenkins and Sturmer, 2012; Van Wijngaarden et al., 1988). 
There are currently no other indications that 5-(2-aminopropyl)indole may be used for other 
legitimate purposes. There are no known uses of 5-(2-aminopropyl)indole as a component in 
industrial, cosmetic or agricultural products.  
There is no information that 5-(2-aminopropyl)indole is currently used in the manufacture of 
a medicinal product in the European Union. However, in the absence of a European Union 
database on the synthetic routes of all medicinal products this information cannot be verified. 
There is no marketing authorisation (existing, ongoing or suspended) for 5-(2-
aminopropyl)indole neither in the European Union nor in the Member States that responded 
to the request for information from the European Medicines Agency (EMCDDA & Europol, 
2012). 
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Section B. Dependence and abuse potential 
B1. Animal in vivo and in vitro data  
No published experimental animal studies were identified that examined the dependence 
and abuse potential of 5-(2-aminopropyl)indole.  
As detailed in section A.2, 5-(2-aminopropyl)indole has been shown to act as a relatively 
potent, selective and reversible inhibitor of monoamine oxidase inhibitor-A (MAO-A) in vitro. 
This suggests that it might either by itself or in combination with other substances potentiate 
serotonergic effects. Although 5-(2-aminopropyl)indole did not inhibit human recombinant 
MAO-B in vitro up to 500 µM (Annex 1), the possibility of increased levels of other 
monoamines such as dopamine and noradrenaline may not be fully excluded. However, 
further studies are needed to investigate the dependence or abuse potential of this 
substance.  
B2. Human data  
There are no published cases in the scientific or grey literature nor user reports describing 
the potential for dependence or abuse potential for 5-(2-aminopropyl)indole. Additionally, 
there have been no studies investigating the dependence and/or abuse potential of 5-(2-
aminopropyl)indole in humans. Information from local, regional or national drug treatment 
agencies about the dependence and abuse potential of 5-(2-aminopropyl)indole is not 
available. As noted, Shulgin and Shulgin (1997) provided some limited information that 5-(2-
aminopropyl)indole may show long-lasting stimulant properties in humans for about twelve 
hours when 20 mg is given orally.  
Section C. Prevalence of use 
Information from seizures, collected and biological samples 
The first official notification of 5-(2-aminopropyl)indole to the European Union Early warning 
system was 1 June 2012 by the Norwegian national focal point. The reporting form details a 
seizure of one zip-lock bag containing one gram of light brown powder intercepted at Oslo 
Airport, Gardermoen, on 17 April 2012 by customs authorities. The identification was based 
on the analytical technique of GC-MS alone.  
Seven Member States (Denmark, Germany, Finland, Hungary, the Netherlands, Sweden 
and the United Kingdom) and Norway have reported seizures of 5-(2-aminopropyl)indole. 
At the time of writing the Joint report, several Member States reported that many forensic 
and/or toxicological laboratories did not have validated procedures for the confirmation of 5-
(2-aminopropyl)indole in seized, collected and biological samples (EMCDDA and Europol, 
2012). The lack of certified reference material has meant that some laboratories could not 
distinguish 5-(2-aminopropyl)indole from the related compound AMT which was also present 
in samples seized on the drug market at the time. Furthermore, in the case of biological 
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samples there is no rapid qualitative screening method for the detection of 5-(2-
aminopropyl)indole. Overall, this may have led to the under-reporting of 5-(2-
aminopropyl)indole. 
5-(2-Aminopropyl)indole has typically been encountered in seizures and collected samples 
in the form of powders, as well as in tablets and capsules. Where information has been 
provided, the quantities of powder ranged from 0.2 grams (Hungary) to 20.5 kilograms (the 
Netherlands). Hungary reported a seizure of seven beige tablets bearing markings 
resembling the Lexus logo (14). This may suggest that 5-(2-aminopropyl)indole is being sold 
as ‘ecstasy’, as Europol have reported that tablets containing MDMA and bearing this logo, 
as well as a tablet punch (for imprinting logos on tablets as part of the manufacturing 
process) have been seized in the past. In Sweden, blue/green unmarked tablets and brown 
glittery tablets were also seized. In the United Kingdom, blue unmarked tablets were seized 
from a head shop and were found in commercial packages marked ‘BENZO FURY’ that also 
displayed an image of the chemical structure of 5-APB (5-(2-aminopropyl)benzofuran) (15). 
There has been one report of residues found on a spoon and one report where 5-(2-
aminopropyl)indole was recovered from the liquid in a syringe (Hungary). This may suggest 
that 5-(2-aminopropyl)indole is being injected by some users. See Annex 1 for details of 
seizures and collected samples reported to EMCDDA and Europol. 
Two collected samples from the United Kingdom that were purchased from Internet retailers 
were found to be consistent with the succinate form of 5-(2-aminopropyl)indole. 
Sweden reported the detection of 5-(2-aminopropyl)indole in ten biological samples (one 
blood; nine urine) from individuals suspected to have committed minor drug offences or 
people that are in drug treatment programmes. Further information on these cases are not 
available. 
Availability from Internet retailers 
A structured Internet search was conducted in March 2013 using the EMCDDA snapshot 
methodology to identify Internet retailers offering 5-(2-aminopropyl)indole for sale (16). Five 
Internet retailers were identified that currently offered the substance for sale to consumers in 
                                                     
(14) It is common to find markings on tablets sold as ‘ecstasy’ including those of popular cultural and iconic brands often 
having an association with quality. Lexus is a Japanese car manufacturer. 
(15) Although Internet retailers typically advertise ‘Benzo Fury’ products (or using synonyms such as ‘BENZO FURY’, 
‘BenzoFury’, ‘Benzo-fury’, ’Benzo’, and ‘Fury’) as containing 6-APB or 5-APB, a structured search of the European 
database on new drugs (EDND) found that seized and collected samples of 'Benzo Fury' products have contained: 6-
APB; 5-APB; D2PM; pentylone with caffeine, lidocaine and procaine; AM-2201 (tentative identification); and, 5-(2-
aminopropyl)indole. Additionally, published studies involving the analysis of collected and biological samples suggest 
that 'Benzo Fury' products contain: 6-APB; 5-APB; D2PM; and, 1-benzylpiperazine (BZP) with 3-
trifluoromethylphenylpiperazine (3-TFMPP) and caffeine (Ayres and Bond, 2012; Baron et al., 2011; Wood et al., 
2011; Wood et al., 2012). 
(16) The Internet search engine ‘google.co.uk’ was searched (March 2013) for Internet retailers offering 5-(2-
aminopropyl)indole for sale. On the advanced search page, Google was configured so that results were not narrowed 
by language and region. The search string used was: buy ‘5-IT’ OR ‘5-API’ OR ‘5-(2-aminopropyl)indole’. The first 
100 sites were reviewed in full then sampling continued until 20 successive sites unrelated to the sale of 5-(2-
aminopropyl)indole were identified. Websites that offered 5-(2-aminopropyl)indole for sale were reviewed and 
relevant information, such as the amount offered (mass of powder, number of capsules/pellets) and cost of purchase 
was recorded on a structured reporting form.  
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the European Union. In addition two further sites were identified that stated that 5-(2-
aminopropyl)indole would be available for sale soon. On two of the sites offering the drug for 
sale all of the 5-(2-aminopropyl)indole products were out of stock and on one of these sites 
the prices given were promotional prices. Between them, the five retailers offered a total of 
21 products for sale that claimed to contain 5-(2-aminopropyl)indole (11 products in powder 
form, two in capsules and eight for which the physical form was not stated). Three sites 
quoted prices in GPB, one in EUR and one did not state the price. Three sites offered 5-(2-
aminopropyl)indole in powder form. The price per gram ranged from 32 to 40 GBP. The 
largest quantity offered for sale was 5 grams at 22.95 GBP per gram. One site offered 5-(2-
aminopropyl)indole in capsule form although no prices were stated. The quantities of 5-(2-
aminopropyl)indole per capsule were 80 mg and 100 mg. The site claimed that the effects of 
the 80 mg capsules last 3–4 hours and those of the 100 mg capsules last 5–6 hours. Some 
of the websites suggested that there is a similarity between 5-(2-aminopropyl)indole and 5-
APB, 6-APB and MPA. No site offered products that contained both 5-(2-aminopropyl)indole 
and other new psychoactive substances. In addition a number of suppliers were identified on 
the trade website tradevv.com that claimed to supply 5-(2-aminopropyl)indole in bulk 
quantities. However, details of the amounts offered and prices were only available on direct 
application to these suppliers. 
Prevalence of use 
No studies were identified that investigated the prevalence of 5-(2-aminopropyl)indole use.  
One Member State reported the detection of 5-(2-aminopropyl)indole in biological samples 
from ten individuals not related to non-fatal intoxications and deaths. The individuals were 
suspected to have committed minor drug offences or were people in drug treatment 
programmes. Information on these cases is not available to allow further analysis. 
In addition, 5-(2-aminopropyl)indole has been detected in a ‘legal high’ product labelled as 
‘Benzo fury’ (see footnote 15). Furthermore, in three non-fatal intoxications ‘Benzo Fury’ was 
the product reported to have been taken.  In several of the fatalities an empty bag labelled 6-
APB (6-(2-aminopropyl)benzofuran) was found, but not detected in post-mortem samples. A 
small number of tablets resembling ecstasy have also been found to contain 5-(2-
aminopropyl)indole. It is therefore relevant to discuss the available prevalence data on the 
use of ‘Benzo Fury’ products, 6-APB and ecstasy.  
Information on the use of ‘Benzo fury’ products and 6-APB 
Two Internet surveys were identified that examined the use of ‘Benzo Fury’. One of these 
also examined the use of 6-APB. While these surveys provide some indication of the use of 
‘Benzofury’ products, the results are not generalisable to other groups and populations as 
they are non-probablistic convenience sample surveys. In addition it is important to note 
both that the surveys predate the detection of 5-(2-aminopropyl)indole on the European drug 
market and a number of different new psychoactive substances have been detected in 
products sold as ‘Benzo Fury’ (see footnote 15). 
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The first survey was conducted among readers of a dance music magazine and the 
Guardian newspaper. It found that, overall, 2.4 % of respondents (n=7,700) and 3 % of 
‘regular clubbers’ from the United Kingdom reported use of ‘Benzo Fury’ in the last year. In 
comparison, the self-reported last year prevalence for ‘regular clubbers’ of mephedrone was 
30 %, MDAI was 3 % and methylone was 2 % (Mixmag, 2012). The second study conducted 
among self-reported users of new psychoactive substance mainly from Ireland (n=329), 
found that of the 159 respondents who reported using 'party pills' and 'liquid highs', 1.3 % 
(2/159) had used a product named 'Benzo Fury'; while none of the respondents reported use 
of '6-APB' (Kelleher et al., 2011). 
Data from National Poisons Information Service (NPIS) in the United Kingdom indicate that 
there has been a small number of telephone calls and Toxbase access requests in relation 
to 6-APB. No information was provided on 5-(2-aminopropyl)indole itself (Health Protection 
Agency, 2012).  
5-(2-Aminopropyl)indole in tablets resembling ‘ecstasy’  
Hungary reported the seizure of seven tablets that contained both 5-(2-aminopropyl)indole 
and methylthienylpropamine bearing markings resembling the Lexus logo (Annex 2). As 
noted, Europol have reported MDMA tablets and a tablet punch (for stamping logos on 
tablets) bearing the Lexus logo have been seized in the past. It may be the case that some 
ecstasy users are at risk of exposure to 5-(2-aminopropyl)indole. In this respect, drug 
prevalence estimates suggest that about 2 million Europeans (aged 15–64) have used 
ecstasy during the last year (17) (EMCDDA and Europol, 2013). However, as noted, the total 
number of such types of tablets containing 5-(2-aminopropyl)indole that have been reported 
so far is small and limited to one country. 
Section D. Health risks 
D1. Acute health effects 
D1.1. Animal data 
No studies were identified that investigated the acute toxicity of 5-(2-aminopropyl)indole in 
experimental animal models.  
While detailed pharmacological investigations on 5-(2-aminopropyl)indole do not appear to 
have been published (18), as noted in section A2., one study was identified that investigated 
the ability of 5-(2-aminopropyl)indole and its five isomers to inhibit monoamine oxidase 
(MAO). The assay method was based on the ability of guinea pig liver homogenate to 
absorb oxygen generated from serotonin as the substrate. The activity was expressed as 
                                                     
(17) European estimates are computed from national estimates weighted by the population of the relevant age group in 
each country. They are based on surveys conducted between 2004 and 2010/11 (mainly 2007–2010) and therefore 
do not refer to a single year. The term ecstasy is used in a broad sense to refer to substances that contain MDMA or 
other substances that are presented as ecstasy.  
(18) As noted in footnote 13, a literature search on 5-(2-aminopropyl)indole revealed a translated article (USSR, Academy 
of Sciences) on serotonergic properties of several tryptamines. However, inspection of the English translation did not 
appear to provide any data on 5-(2-aminopropyl)indole (Buznikov et al., 1965). 
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percentage inhibition. The IC50 values for 5-(2-aminopropyl)indole, 6-(2-aminopropyl)indole 
(6-IT) and 3-(2-aminopropyl)indole (AMT), for example, were 22, 4.6 and 58 µM, 
respectively. These data indicate that the 6-IT isomer was the most potent inhibitor amongst 
those three substances. These substances were also evaluated for their ability to antagonise 
pentylenetetrazole/reserpine-induced tonic extensor seizures in mice. 5-(2-
Aminopropyl)indole appeared to be less active than 6-IT but more active than the AMT 
isomer with regards to anti-reserpine activity (Cerletti et al., 1968). AMT has been shown to 
induce stimulant effects in mice (incl. body tremor, heightened locomotor activity, mydriasis 
and hyperthermia) (Lessin et al., 1965), the extent to which this extends to the remaining 
isomers, including 5-(2-aminopropyl)indole, remains to be studied. A short report on the 6-
(2-aminopropyl)indole isomer provided some indication that intravenous administration (0.5 
mg/kg) resulted in hypertension and related sympathomimetic features in dogs (Maxwell, 
1964). 
D1.2. Human data 
D1.2.1. User reports 
As noted, Shulgin and Shulgin (1997) reported that 5-(2-aminopropyl)indole may show long-
lasting stimulant properties in humans of about twelve hours following oral administration of 
20 mg. Effects reported were increased heart-rate, anorexia, diuresis, and slight 
hyperthermia. No further information was provided. 
There are some user reports on drug discussion forums that discuss the use of 5-(2-
aminopropyl)indole (e.g. 19). These need to be interpreted with caution as there was no 
analytical confirmation of the substances used. In addition, some of the users describe 
taking other drugs prior to or with 5-(2-aminopropyl)indole. 
Some of the websites suggest that there is a structural similarity between 5-(2-
aminopropyl)indole and 5-ABP, MPA and AMT. In addition one websites alludes to 5-(2-
aminopropyl)indole having similar effects to 5-APB while another lists the product as ‘5-IT 
(similar to 6-APB)’. 
Drug Forum: 
The first discussion thread on the Drug Forum website for 5-(2-aminopropyl)indole appears 
to have been started in August 2010; while the first user report relating to this substance 
appears to be in November 2011. The thread also includes reference to 5-(2-
aminopropyl)indole as an isomer of AMT, with citation of various on-line reference sources 
(e.g. Wikipedia) as well as Shulgin and Shulgin’s ‘TiKHAL’ (1997). 
User reports 
                                                     
(19)  http://www.drugs-forum.com/forum/showthread.php?t=140331  
http://www.drugs-forum.com/forum/showthread.php?t=172223 
http://www.drugs-forum.com/forum/showpost.php?p=1126167&postcount=9 
http://www.bluelight.ru/vb/threads/616728-The-Big-amp-Dandy-5-IT-5-API-Thread 
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One user after an apparent intravenous injection of 5-(2-aminopropyl)indole reported 
‘incredible rush, not so strong stimulating properties like speed, feeling is more like.. aMT + 
weak speed’. Another reported ‘very small psychedelic properties, reminds [me] of aMT’. 
Following 80 mg ‘bombed’ a user concluded that ‘I would say this somewhere in effects 
between 6-APB and MDAI with an amphetamine like quality but also quite reminiscent of 
aMT just nowhere near as psychedelic and with no nausea or body load’. Another user who 
‘bombed’ 100 mg of 5-(2-aminopropyl)indole summarised ‘no come down, very stable 
euphoria and clear thoughts with a little bit of trippiness’. The use of 6-APB was mentioned 
by a number of users and one indicated a comparison stating that 5-(2-aminopropyl)indole 
was ‘quite comparable to 6-APB, but not quite as debilitating in its intenseness, not as 
euphoric, with a slightly shorter duration’. 
Bluelight: 
Amongst initial user discussions regarding the relative risk of taking ‘new research 
chemicals’ such as 5-(2-aminopropyl)indole and making predictions of effects, one user who 
took 20 mg (unknown route) stated that ‘the duration on 5-IT is rather long, with the entire 
experience lasting about 10 hours, probably slightly more’. Similar duration of effect was 
also noted by another user who had taken 100 mg: ‘I still felt it after seven hours on a 100mg 
dose’. However, another user in response to an extended come down experience of 22 
hours postulated whether the user had actually taken 5-(2-aminopropyl)indole. Dose 
discussions also featured and one user surmised that ‘at high doses I have seen reports of 
dysphoria, delirium, pain, unconsciousness, confusion, hyperthermia, tremors. I experienced 
only positive effects but I would not recommend a higher starting dose for these reasons’. 
D1.2.2. 5-(2-Aminopropyl)indole associated acute toxicity 
Two Member States (Sweden and the United Kingdom) reported a total of 20 non-fatal 
intoxications associated with 5-(2-aminopropyl)indole.  
German police reported to Europol a case where a powder was seized from an unconscious 
person. It is not known if this is a non-fatal intoxication associated with 5-(2-
aminopropyl)indole as further details are not available and therefore has not been included 
in this report. 
Non-fatal cases reported by Sweden 
Sweden reported 18 non-fatal intoxications where 5-(2-aminopropyl)indole was detected in 
biological samples. They occurred between January and August 2012. 
Of the 18 cases, 16 were male and two were female. Their ages ranged between 17 and 53, 
however the most common age was 20 to 30 years with 11 of the 18 falling into this bracket. 
In six cases, the individual stated they had taken ‘5-IT’ (a commonly used abbreviation for 5-
(2-aminopropyl)indole), in three cases the stated intake was ‘benzofury’. Other cases 
mentioned taking ethylphenidate, etizolam, MDPV and/or 6-APB. One person said they had 
been ‘drinking only coca cola from an unknown source’; another person stated they had 
taken ‘an unknown substance’. 5-(2-Aminopropyl)indole was analytically confirmed in each 
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case although the concentration was not determined. Other drugs detected in these cases 
were: ethylphenidate, 4-,5- or 6-APB, 4-methylethcathinone, buprenorphine, 
methylphenidate (and metabolites), 4-fluoroamphetamine, oxazepam, temazepam, 
diazepam metabolites, methylthienylpropamine, methoxetamine, 4-hydroxymidazolam 
(midazolam metabolite), ketamine, GHB (gamma-hydroxybutyrate), PMMA (para-
methoxymethamphetamine), amphetamine, N-methamphetamine, 4-methylamphetamine, α-
PVP, cannabis, thiopental, pentobarbital, benzoylecgonine (cocaine metabolite), ethanol and 
metabolites. It is not known whether any of these substances (e.g. benzodiazepines and 
barbiturates) had been administered as part of medical treatment. 
The route of administration of 5-(2-aminopropyl)indole was indicated in two cases where the 
individuals reported having taken it by nasal insufflation. In three cases the individuals 
reported that they had sourced 5-(2-aminopropyl)indole from the Internet. The sources of 5-
(2-aminopropyl)indole for the remaining fifteen cases are not available. 
The reported symptoms included dilated pupils, sweating, restlessness, fatigue, 
disorientation, agitation, mydriasis, anxiety, tachycardia, hypertension and hyperpyrexia. 
Hallucinations were mentioned in one individual where 5-(2-aminopropyl)indole and 
benzodiazepines were detected only (20). 
Non-fatal cases reported by the United Kingdom 
The United Kingdom reported two non-fatal intoxications associated with the second death 
case that is detailed in section D1.2.3. The two individuals had also reportedly ingested 
‘Benzo Fury’ from the same source as the deceased. They were also examined at the 
hospital but neither appeared to have suffered any significant toxic effects. No further 
information on drug history or the amounts of ‘Benzo Fury’ taken is available. 
D1.2.3. 5-(2-Aminopropyl)indole associated deaths 
Four Member States (Sweden, the United Kingdom, Hungary and Germany) reported a total 
of 24 deaths associated with 5-(2-aminopropyl)indole (Table 3). 
Deaths reported by Sweden 
Sweden reported 15 deaths associated with 5-(2-aminopropyl)indole. The deaths occurred 
between April 2012 and July 2012. In 14 of the cases the cause of death was considered to 
be related to 5-(2-aminopropyl)indole. In the remaining case the cause was ‘disease’. In the 
large majority of cases the cause of death was considered to be drug related although the 
ICD10 coding does not include naming 5-(2-aminopropyl)indole specifically. In the remaining 
cases, the cause was not ICD10 coded as being drug related and were recorded as being 
due to epilepsy and in another case, sudden cardiac arrest. In 14 cases the 5-(2-
                                                     
(20)  The example provided in the Joint report of a non-fatal intoxication involving an eighteen year old female who had  
taken one capsule of 5-(2-aminopropyl)indole of unknown strength actually relates to a self report that was not 
analytically confirmed. Although in the text of the Joint report it appears that this case was one of the 13 non-fatal 
intoxications reported by Sweden, further information from the national focal point has confirmed that it was not part 
of this case series and instead was documented prior to the introduction of biological screening for 5-(2-
aminopropyl)indole. See EMCDDA & Europol (2012) for details further details of this case.  
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aminopropyl)indole concentration in post-mortem femoral blood ranged from between 0.7 
and 5.1 µg/g blood. In one case the concentration of 5-(2-aminopropyl)indole was 18.6 µg/g 
femoral blood. All of the decedents were male. 13 were aged between 20 and 30 years, the 
remaining two were over 30 years old. In two cases 5-(2-aminopropyl)indole was the only 
substance reported as detected. In the remaining cases 5-(2-aminopropyl)indole was found 
in combination with ‘pharmaceuticals’ or ‘other drugs of abuse’. Notably some of these drugs 
have monoaminergic activity, such as sertraline, venlafaxine and MDMA. 
Deaths reported by Hungary 
Hungary reported four deaths associated with 5-(2-aminopropyl)indole.Two of these deaths 
occurred in April 2012 and were originally believed to be related to AMT which was reported 
as detected in post-mortem biological samples. The decedents, a 40-year-old male and a 
35-year-old female were found together in a flat.  
The post-mortem concentrations determined as AMT were 34 mg/L and 84 mg/L 
respectively. These figures are provided only to show them relative to each other. The 
biological samples were no longer available for re-analysis. However, the reanalysis of 
powders found at the scene identified the presence of 5-(2-aminopropyl)indole and not AMT. 
The Hungarian national focal point noted that ‘based on the active agent identified in the 
substance found next to the bodies it is assumed that the cause of the deaths was 5-(2-
aminopropyl)indole intoxication rather than AMT intoxication’. As already noted, analytical 
reference standards were not available at the time and it was difficult to distinguish between 
5-(2-aminopropyl)indole and AMT. No other substances were reported as detected. 
The pathological cause of death in each case was ‘circulatory failure and respiratory failure, 
where the direct causes of death… were the results of 5-IT intoxication’ and in the case of 
the female ‘the respiration of vomited content of stomach might have had a limited impact 
too’. There were signs of ‘prolonged sexual intercourse, extreme hyperthermia and the use 
of new psychoactive substances’. 
The third death occurred in May 2012, an involved a 38 year old male known ‘drug abuser’ 
who was found dead in his apartment along with injection paraphernalia. A sachet found 
next to the body contained 5-(2-aminopropyl)indole. ‘The toxicological analysis identified 5-
IT in the blood’ but no quantitative information was available. No other substances were 
reported as detected. The cause of death was attributed to drug intoxication and respiratory 
failure. 
The fourth death occurred in June/July 2012, a 24 year old male died having purchased a 
product called ‘Pink’ from the Internet. The substance had been dissolved in water and 
consumed. ‘Toxicological analysis identified 5-IT in the blood and stomach’. No other 
substances were reported as detected. The cause of death was attributed to circulatory and 
respiratory failure as a result of drug use and overdose.  
Deaths reported by the United Kingdom 
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The United Kingdom reported four deaths associated with 5-(2-aminopropyl)indole. Details 
are only provided for two of these cases, both of which occurred in June 2012. The 
decedents were both male; one was 33 years old, the other was 19 years old. 
The cause of death in the first case involving the 33 year old was ‘fatality following the 
ingestion of ‘Benzo Fury’’ and certified as ‘5-(2- aminopropyl)indole (5-API; 5-IT) and 
Benzofuran toxicity’. The male was treated in hospital prior to death. Analysis of the blood 
revealed an approximate 5-(2-aminopropyl)indole concentration of 0.379 mg/L in 
unpreserved post-mortem blood. Other drugs detected in the blood included 5-APB (0.016 
mg/L), 6-APB (0.057 mg/L), diazepam (0.037 mg/L), nordiazepam (0.009 mg/L), temazepam 
(0.001 mg/L) and AMT (less than 0.01 mg/L). Urine analysis detected amphetamine, 5-(2-
aminopropyl)indole, 5-APB, 6-APB, AMT and benzodiazepines. In addition, 5-(2-
aminopropyl)indole, 5-APB, 6-APB, AMT and diazepam were detected in the stomach 
contents. 
In the second case involving the 19 year old, the toxicological investigation revealed 5-(2-
aminopropyl)indole at a concentration of approximately 0.513 mg/L in ante-mortem blood 
(the deceased was admitted to hospital prior to death) and approximately 0.30 mg/L in 
unpreserved post-mortem blood. Other drugs detected included MDMA (0.468 mg/L ante-
mortem blood, 0.502 mg/L post-mortem blood), MDA (0.036 mg/L ante-mortem blood, 0.046 
mg/L post-mortem blood), 6-APB (0.005 mg/L post-mortem blood only), atropine and 
lignocaine. These drugs were also detected in the urine and stomach contents. It was noted 
that there was a high concentration of MDMA, which on its own was considered to be at a 
fatal level. However, a cumulative/synergistic effect of 5-(2-aminopropyl)indole was not 
excluded and the cause of death was recorded as ‘multidrug toxicity’. This case is linked to 
the seizure of 116 blue tablets in branded packets labelled as ‘BENZO FURY’ that were 
found to contain 5-(2-aminopropyl)indole. 
The remaining two deaths were reported in a letter to the British Medical Journal. The letter 
reports that 5-(2-aminopropyl)indole was detected in the post-mortem blood samples of two 
young adults. The authors note that 5-(2-aminopropyl)indole was ‘found in combination with 
other drugs in one case’; while in the second case ‘5-APB/6-APB’ was detected (Seetohul et 
al., 2012). It was ascertained from the national focal point that these cases were distinct 
from the other two cases reported by the United Kingdom. No further details are available at 
this time. 
Death reported by Germany 
Germany reported one death associated with 5-(2-aminopropyl)indole. 
The report stated that on 23 May 2012, a 29 year old man who was not known as drug user 
was found dead in his apartment. A powder was found under his bed which was analysed 
and found to contain 5-(2-aminopropyl)indole. The initial urine screen indicated a positive 
result for amphetamine/methamphetamine. The preliminary autopsy report provided ‘neither 
a hint on external assault and battery nor on a pathological-anatomic cause of death’. 
Further toxicological investigations revealed a high concentration of 5-(2-aminopropyl)indole 
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in the blood and urine samples (the blood sample contained >1200 ng/ml) (Schäper et al., 
2013). No other substances were reported as detected. The final cause of death has not yet 
been recorded however, the German national focal point reported that intoxication by 5-(2-
aminopropyl)indole is plausible. 
This case highlights that there may be cross-reactivity issues with some screening tests. 
Further research is required to investigate this. 
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Table 3. Summary of deaths associated with 5-(2-aminopropyl)indole (5-IT). For reference against 
other reported cases µg/g is largely comparable to mg/L. 
 
Date 
of 
death 
Decease
d 
(age/sex
) 
5-(2-
Aminopropyl)
indole 
toxicological 
findings 
(blood) 
Other drugs 
detected (blood 
unless otherwise 
indicated) 
 
ICD10 coding or descriptive cause of death 
 
 
Sweden 
 
April 
2012 
23 yr old 
male 
18.6 µg/g AM2201 
4-APB (urine) 
Toxic effects of non-medicinal substance 
May 
2012 
31 yr old 
male 
2.3 µg/g 0.05 µg/g hydroxyzine 
0.04 µg/g etizolam 
Poisoning by hallucinogen 
May 
2012 
24 yr old 
male 
2.4 µg/g 0.03 µg/g zopiclone   
0.003 µg/g 
ethylphenidate 
0.03 µg/g ritalinic acid 
Un-attended death. No other cause found. 
May 
2012 
28 yr old 
male 
3.8 µg/g 26 µg levitiracetam Epilepsy 
May 
2012 
20 yr old 
male 
1.1 µg/g 0.02 µg/g 
benzoylecgonine 
0.002 µg/g THC   
pentedrone [no 
quantitative data 
provided] 
Sudden cardiac arrest 
May 
2012 
31 yr old 
male 
5.1 µg/g 0.04 µg/g 7-amino-
clonazepam 
0.01 µg/g 
perphenazine 
0.12 µg /g 
ethylphenidate  
2.6 µg/g ritalinic acid 
0.0002 µg/g 
methylphenidate  
Poisoning by drugs 
May 
2012 
33 yr old 
male 
4.2 µg/g   Poisoning by hallucinogen 
May 
2012 
28 yr old 
male 
2.5 µg/g  9.2 µg/g pregabalin Poisoning by drugs 
May 
2012 
40 yr old 
male 
1.0 µg/g   Poisoning by hallucinogen 
June 
2012 
31 yr old 
male 
1.6 µg/g  0.2 µg/g alimemazine 
0.1 µg/g 
desmethylalimemazin
e 
Un-attended death. No other cause found 
June 
2012 
29 yr old 
male 
0.7 µg/g  0.18 µg/g 
ethylphenidate 
1.9 µg/g ritalinic acid 
Accidental poisoning by drugs 
June 
2012 
55 yr old 
male 
2.1 µg/g  0.9 µg/g carisoprodol 
meprobamate (not 
quantitated)   0.32 
µg/g 7-amino-
clonazepam 
Poisoning by drugs 
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June 
2012 
30 yr old 
male 
2.1 µg/g  0.7 µg/g sertraline 
2.5 µg/g 
desmethylsertraline 
1.0 µg/g venlafaxine 
0.5 µg/g o-
desmethylvenlafaxine 
Poisoning by drugs 
June 
2012 
24 yr old 
male 
1.1 µg/g  0.02 µg /g 
benzoylecgonine 
0.53 µg/g MDMA 
0.03 µg/g MDA 
Poisoning by hallucinogen 
July 
2012 
28 yr old 
male 
1.7 µg/g  0.008 µg/g 
ethylphenidate 
Un-attended death. No other cause found 
Hungary 
April 
2012 
40 yr old 
male 
Not available None Circulatory failure and respiratory failure were 
the direct causes of death that were the results 
of 5-IT intoxication. 
April 
2012 
35 year 
old 
female 
Not available None Circulatory failure and respiratory failure were 
the direct causes of death that were the results 
of 5-IT intoxication, the respiration of vomited 
content of stomach might had a limited inpact 
too. 
May 
2012 
38 year 
old male 
Not available None Brain oedema, frothy respiratory tract 
secretion, pulmonal oedema and minor 
degeneration of cardiac muscle were observed 
in the body. The report concludes that based 
on the case history and the diagnostic report 
drug intoxication and respiratory failure as a 
consequence of intoxication are the assumed 
causes of death. 
June/J
uly 
2012 
24 year 
old male 
Not available None The cause of death was circulatory and 
respiratory failure that developed due to 
metabolic failure, severe brain oedema, 
pulmonal oedema and cardiac failure. The 
report concludes that, in all probability, the 
cause of that was drugs use and overdose. 
United Kingdom 
June 
2012 
33 year 
old male 
0.379 mg/L  0.016 mg/L 5-APB 
0.057 mg/L 6-APB 
0.037 mg/L diazepam 
0.009 mg/L 
nordiazepam 
0.001 mg/L 
temazepam 
<0.001 mg/L AMT 
 
The level of 5-IT is an approximate 
determination in unpreserved post mortem 
blood. 
All other analytes were detected in post 
mortem blood. 
Urine analysis detected amphetamine, 5-IT, 5-
APB, 6-APB, AMT and benzodiazepines. 
In addition, 5-IT, 5-APB, 6-APB, AMT and 
diazepam were detected in the stomach 
contents  
June 
2012 
19 year 
old male 
0.30 mg/L  
 
0.502 mg/L MDMA 
0.046 mg/L MDA 
0.005 mg/L 6-APB 
Atropine 
Lignocaine 
The level of 5-IT is an approximate 
determination in unpreserved post mortem 
blood. 0.513 mg/L 5-IT was determined in ante 
mortem blood 
Cause of death noted to be ‘multi-drug 
toxicity’. 
All other analytes were detected in post 
mortem blood. 
Prior to 
24 
August 
2012 
‘young 
adult’ 
Not available ‘Other drugs’ Reported in letter to the British Medical 
Journal, no further details available. 
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Prior to 
24 
August 
2012 
‘young 
adult’ 
Not available ‘5/6-APB’ Reported in letter to the British Medical 
Journal, no further details available. 
Germany 
May 
2012 
29 year 
old male 
>1200 ng/ml None The final cause of death has not yet been 
recorded however, the national focal point 
reported that intoxication by 5-(2-
aminopropyl)indole is plausible. 
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D2. Chronic health effects 
D2.1. Animal data 
No studies were identified that investigated the chronic health effects of 5-(2-
aminopropyl)indole in animals. 
D2.2. Human data 
No studies were identified that investigated the chronic health effects of 5-(2-
aminopropyl)indole in humans. 
D3. Factors affecting public health risks 
D3.1. Availability and quality of the new psychoactive substance on the market  
5-(2-Aminopropyl)indole is offered for sale by Internet retailers as a substance in its own 
right. 5-(2-Aminopropyl)indole has also been detected in a ‘legal high’ type product branded 
as ‘Benzo Fury’. There has also been one report from Hungary where 5-(2-
aminopropyl)indole was seized as tablets resembling ‘ecstasy’. Some individuals may be 
exposed to 5-(2-aminopropyl)indole intentionally. Others may be exposed unintentionally 
and unknowingly after consuming a product with no indication that it contains 5-(2-
aminopropyl)indole or following its ingestion as a component of a mixture of other active 
substances (e.g. MDAI, 5- or 6-APB). 
D3.2. Availability of the information, degree of knowledge and perceptions amongst 
users concerning the psychoactive substance and its effects 
There is relatively limited information on drug discussion forums regarding the effects and 
potential health / adverse effects related to the use of 5-(2-aminopropyl)indole. On some 
drug discussion forums the use of 5-(2-aminopropyl)indole as a drug in its own right has 
been discussed. This is supported by the finding that two collected samples from Internet 
retailers contained 5-(2-aminopropyl)indole (in powders) as well as the fact that Internet 
retailers offer various dosage forms claiming to contain the substance (section C). 
Nevertheless, it is likely that the information, degree of knowledge, and perceptions amongst 
users concerning 5-(2-aminopropyl)indole and its effects are likely to be limited. In addition 
some users may be exposed to 5-(2-aminopropyl)indole unknowingly given that it has been 
detected in a ‘legal high’ type product labelled as ‘Benzo Fury’ as well as tablets resembling 
ecstasy. 
D3.3. Characteristics and behaviour of users  
There are self-reports from users on drug discussion forums who believe that they have 
specifically taken 5-(2-aminopropyl)indole. In some cases this appears to be in order to 
determine its relative effects compared to related compounds such as AMT in particular as 
well as 5- or 6-APB. This suggests a degree of risk-taking behaviour although some of the 
discussions have included harm reduction measures in relation to use of ‘new research 
chemicals’.  
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D3.4. Nature and extent of health consequence  
The limited documented information on the acute health effects of 5-(2-aminopropyl)indole 
have been discussed in section D1.2. There is insufficient information in the reported non-
fatal intoxications and deaths where 5-(2-aminopropyl)indole has been detected to discuss 
in detail the circumstances of these cases. However, from the information available, it does 
not appear that any of these were related to road traffic accidents. The information available 
indicates that the presence of 5-(2-aminopropyl)indole has been analytically confirmed in a 
number of acute emergencies associated with the substance. 
D3.5. Long-term consequences of use 
As noted in sections D2.1. and D2.2. no animal or human data on the chronic health effects 
of 5-(2-aminopropyl)indole were identified. In particular, there have been no long-term follow 
up studies to determine whether 5-(2-aminopropyl)indole users are at greater risk of health 
deterioration later in life, or of developing chronic or life-threatening medical conditions. 
D3.6. Conditions under which the new psychoactive substance is obtained and used, 
including context-related effects and risks 
As noted, it appears that the sourcing and use of 5-(2-aminopropyl)indole is generally 
related to individuals attempting to source the drug itself or when it has been inadvertently 
taken along with or instead of other stimulants. As noted in section C, the structured Internet 
search conducted by the EMCDDA identified five English-language Internet retailers that 
offered 5-(2-aminopropyl)indole for sale to consumers in the European Union. In addition, in 
one case 5-(2-aminopropyl)indole was detected in a ‘legal high’ type product labelled as 
‘Benzo Fury’ that was sold in a bricks and mortar headshop. It is likely that 5-(2-
aminopropyl)indole is used in the same environments as other stimulants. This would be 
typically, but not restricted to, home environments, bars/pubs, discotheques/nightclubs and 
outdoor music festivals. Limited information from drug discussion forums suggest that 5-(2-
aminopropyl)indole is used at home and in nightclubs. 
Section E. Social Risks 
E1. Individual social risks 
There is currently no data to be able to determine the impact of 5-(2-aminopropyl)indole in 
this area. 
E2. Possible effects on direct social environment  
There is currently no data to be able to determine the impact of 5-(2-aminopropyl)indole in 
this area. 
E3. Possible effects on society as a whole 
Sweden reported the detection of 5-(2-aminopropyl)indole in ten biological samples (one 
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blood; nine urine) from individuals suspected to have committed minor drug offences or 
people that are in drug treatment programmes. Further information on these cases are not 
available to allow further comment. 
E4. Economic costs 
Given the lack of data available on acute health emergencies and healthcare utilisation 
related to the use of 5-(2-aminopropyl)indole, it is not possible at this time to estimate 
whether the substance is associated with greater healthcare costs than other stimulant 
drugs. 
E5. Possible effects related to the cultural context, for example marginalisation 
There is currently no data to be able to determine the impact of 5-(2-aminopropyl)indole in 
this area. 
E6. Possible appeal of the new psychoactive substance to specific population 
groups within the general population 
There is currently no data to be able to determine the possible appeal of 5-(2-
aminopropyl)indole to specific population groups within the general population. 
Section F. Involvement of organised crime 
F1. Evidence that criminal groups are systematically involved in production, 
trafficking and distribution for financial gain 
No information has been received by Europol of evidence that criminal groups are 
systematically involved in production, trafficking and distribution of 5-(2-aminopropyl)indole 
for financial gain. 
F2. Impact on the production, trafficking and distribution of other substances, 
including existing psychoactive substances as well as new psychoactive 
substances 
Based on the information available to ECMDDA and Europol it does not appear that the 
production, trafficking and distribution of 5-(2-aminopropyl)indole impacts on other existing 
psychoactive substances or new psychoactive substances. 
F3. Evidence of the same groups of people being involved in different types of 
crime 
No information has been received by Europol of evidence of the same groups of people 
being involved in different types of crime in connection with 5-(2-aminopropyl)indole. 
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F4. Impact of violence from criminal groups on society as a whole or on social 
groups or local communities (public order and safety) 
No information has been received by Europol on incidents of violence in connection with 5-
(2-aminopropyl)indole. 
F5. Evidence of money laundering practices, or impact of organised crime on 
other socioeconomic factors in society 
No information has been received by Europol on incidents of money-laundering or impact of 
organised crime on other socioeconomic factors in society in connection with 5-(2-
aminopropyl)indole. 
F6. Economic costs and consequences (evasion of taxes or duties, costs to 
the judicial system)  
There is currently no data to be able to determine the impact of 5-(2-aminopropyl)indole in 
this area. 
F7. Use of violence between or within criminal groups 
No information has been received by Europol on incidents of violence in connection with 5-
(2-aminopropyl)indole. 
F8. Evidence of strategies to prevent prosecution, for example through 
corruption or intimidation 
No information has been received by Europol on strategies to prevent prosecution in 
connection with 5-(2-aminopropyl)indole.
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Annex 1 
Details of seizures and collected samples of 5-(2-aminopropyl)indole (5-IT) reported to 
the EMCDDA and Europol 
 
Date of 
seizure or 
collection 
Amount and 
physical form 
Seizing or 
collecting 
authority 
Place of 
seizure or 
collection 
Notes Images 
 
Denmark 
19/07/2012 One seizure of 
5.1 g light 
brown powder  
Customs  Haderslev Powder was found in a small 
transparent bag and with a sticker: 
‘5g 5-IT, Research Chemical, Not 
for human consumption’. The bag 
was inside a ‘normal’ brown 
envelope, and without any sender. 
The post came from United 
Kingdom. Identification based on 
GC-MS, UPLC-TOF, H-NMR. 
 
 
 
Finland 
01/04/2012 One seizure of 
1.1 g of a light 
brown powder 
Customs Helsinki Seized in incoming mail. 
Identification based on NMR. 
 
Germany 
02/05/2012 1.35 g and a 
further 0.22 g 
together with 
traces of MDAI 
(together with 
other new 
psychoactive 
substances) 
 
 
 
 
 
 
Police  Hannover The accused stated that he has 
bought the substances via the 
internet from an online shop in the 
United Kingdom. 
 
 
 
12/11/2012 Brown glittery 
tablets (amount 
unknown at 
present 
Police Bavaria ‘Further fragmentary information on 
5 additional cases of detection of 5-
IT in sezizures [sic] of 1-10 tablets 
per case was reported by the 
Bavarian Police and one case of 1 
gram 5-IT.’ 
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Hungary* 
04/2012 2.4 g of a beige 
powder 
Police Tapolca Confirmed as 5-(2-
aminopropyl)indole 
 
04/2012 Residues on 
paper, liquid in 
syringe (0.75 
ml) 
Police Debrecen Confirmed as 5-(2-
aminopropyl)indole 
 
04/2012 2.2 g of a brown 
powder 
Police Szombathel
y 
Confirmed as 5-(2-
aminopropyl)indole 
 
05/2012 Residues on 
spoon  
Police Szentes Confirmed as 5-(2-
aminopropyl)indole 
 
05/2012 10.2 g of a 
brown powder 
Police Tata Confirmed as 5-(2-
aminopropyl)indole 
 
06/2012 0.2 g of a light-
brown powder 
Police Szigetvár Confirmed as 5-(2-
aminopropyl)indole 
 
06/2012 7 beige tablets 
with ‘Lexus’ 
logo, also 
containing, 
methylthienylpro
pamine and 
caffeine 
Police Kiskőrös Confirmed as 5-(2-
aminopropyl)indole. Weight of 
tablets: 0.285 g, diameter: 8.10 
mm, thickness: 5.8 mm. The 
identification was carried out by 
TLC and GC/MS based on the 
laboratory’s ‘own’ reference 
materials (their structure was 
confirmed by NMR). 
 
07/2012 0.2 g of brown 
powder 
Police Esztergom Confirmed as 5-(2-
aminopropyl)indole 
 
08/2012 97.3 g of a 
brown powder, 
residues on 
digital scale 
Police Szigetvár In this case the investigation 
confirmed the fact of dealing both 
new psychoactive substances 
(according to schedule “C” Gov. 
Decree 66/2012) and illicit drugs 
(covered by the illicit drugs 
definition of the Penal Code). Mail 
delivery and selling from the flat 
was also confirmed. The business 
covered the whole country did not 
concentrate on the area of 
Szigetvár. 
 
09/2012 4.1 g of light 
brown powder 
Police Eger Confirmed as 5-(2-
aminopropyl)indole 
 
10/2012 0.3 g of light 
brown powder 
Police Debrecen Confirmed as 5-(2-
aminopropyl)indole 
 
12/2012 0.1 g of brown 
powder 
Police Szekszárd Confirmed as 5-(2-
aminopropyl)indole 
 
Netherlands 
Not available 20.5 kg Customs 
 
Not available 
 
Sweden 
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33 seizures 
incorporating 
36.33 g powder 
and 54 tablets. 
Police 
 
The first seizure comprising 13 g 
beige powder was seized by the 
police 16/05/2012 in Örnsköldsvik 
city with identification based on 
GC-MS, GC-IRD and NMR.  
 
Examples of seized tablets: One 
type of tablet in 6 materials: These 
are blue, green melange; round 
and curved with border; diameter 
9.0 mm, width 4.0 mm, weight 0.25 
g. Another type of tablet that 
occurred only in one material: 
brown, glittery tablet; round and flat 
and scored; diameter 6.0 mm, 
width 2.9 mm, weight 0.10 g. 
 
 
Four seizures in 
total, 
comprising: 
three seizures 
of a brown 
powder weight a 
total of 11.07 g. 
One seizure of 
5 tablets 
Customs Arlanda 
Airport, 
Sweden 
The three packages containing 
powder were from Spain. The 
package containing tablets were 
sent from United Kingdom. 
 
 
 
 
United Kingdom 
April 2012 500 mg brown 
powder 
State’s 
Analyst 
Guernsey 
Purchased 
from the 
Internet 
Confirmed as 5-(2-
aminopropyl)indole succinate by 
NMR. 
 
 
 
May 2012 Pale brown 
powder  
TicTac Ltd. Purchased 
from 
Internet 
£22.50 for 
500 mg 
Product label stated ‘5-IT’ ‘500mg’ 
‘NOT FOR HUMAN 
CONSUMPTION’. 
 
Analysis by GCMS. Molecular 
formula confirmed by High Res MS. 
Confirmed as 5-(2-
aminopropyl)indole succinate by 
proton NMR.  
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09/06/2012 One seizure of 
116 packets. 
Blue unmarked 
tablet in packet 
Police Edinburgh, 
Scotland 
During the police investigation of 
one of the fatal cases from the 
United Kingdom where the 
presence of 5-(2-
aminopropyl)indole was confirmed, 
the police were informed that the 
product consumed by the deceased 
had been purchased at a 
'headshop' in Edinburgh. Police 
executed a search warrant at the 
Edinburgh premises and recovered 
a large quantity of items (160 
productions) including bulk 
quantities of powders, herbal 
material and packaged products.  
One of the items submitted to the 
Forensic Science Laboratory 
contained 116 yellow packages 
labelled 'BENZO FURY’ with a 
graphic displaying the structure of 
5-APB. Four of these packages, 
selected at random, were examined 
and each found to contain a single 
blue unmarked biconvex tablet 
which were each analysed and 
found to contain 5-(2-
aminopropyl)indole. Other items of 
interest recovered from the 
'headshop' were: Yellow capsules 
labelled 'benzofury' found to 
contain brown powder containing 
5/6-APB. 31 g of brown powder 
found to contain 5/6-APB. 174 
packages (98 of one type and 76 of 
a second type) each containing 1 g 
of crystalline substance identified 
as methylthienylpropamine (MPA). 
 
 
08/09/2012 One seizure of 
seven red and 
white gelatine 
capsules with 
no markings on 
them. Also 
contained 
diphenyl prolinol 
(D2PM). 
Customs Guernsey The Guernsey Border Agency 
seized the capsules along with a 
number of Class B substances from 
a person arriving on the Island. 
Analysis was carried out by the 
Guernsey States Analyst. 
 
Norway 
17/04/2012 One seizure of 
1 g in a small 
bag with zip-
lock  
Customs Gardermoen
, Oslo 
Airport 
Identified with MS only. 
 
 
 
*The Forensic Institute of the National Tax and Customs Administration of Hungary reported no seizures of 5-(2-
aminopropyl)indole. 
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Appendix 1 
Study examining the inhibition of human monoamine oxidase (MAO) by the new 
psychoactive substance 5-(2-aminopropyl)indole, CC.13.SAT.003, February 2013, Herriaz, 
T., in collaboration with Simon D. Brandt.  
 
